Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lohrisch

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Current Oncology (Toronto, Ont.)|June 20, 2015
Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experienceE Baxter, L Gondara, C Lohrisch, et al.
Current Oncology (Toronto, Ont.)|June 4, 2020
Impact of Recurrence Score on type and duration of chemotherapy in breast cancerK Willemsma, W Yip, N LeVasseur, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanesA Awada, L Biganzoli, T Cufer, et al.
Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancerJ A Davidson, I Cromwell, S L Ellard, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Current Oncology (Toronto, Ont.)|June 20, 2015
Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experienceE Baxter, L Gondara, C Lohrisch, et al.
Current Oncology (Toronto, Ont.)|June 4, 2020
Impact of Recurrence Score on type and duration of chemotherapy in breast cancerK Willemsma, W Yip, N LeVasseur, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanesA Awada, L Biganzoli, T Cufer, et al.
Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancerJ A Davidson, I Cromwell, S L Ellard, et al.
Pageof 2